# Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

> **NCT00632203** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 53 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma
- Carcinoma, Large Cell
- Carcinoma, Squamous Cell

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00632203
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03-04
- **Primary completion:** 2011-01-06
- **Final completion:** 2011-01-07
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632203, "Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00632203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*